Entering text into the input field will update the search result below

BMNDF Biomind Labs Inc.
Stock Price & Overview

$0.520.00 (0.00%)11:38 AM 08/22/23
OTCQB | $USD | Market Close


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

Company Profile

Biomind Labs Inc. logo
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammatory disorders, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.
  • Building Ceibo Of. 002
  • Camino Saravia s/n
  • 91.000, Pando
  • Canelones
  • Uruguay
Phone Number
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.